It features GlucoVantage, a bioactive form of berberine that helps maintain healthy GLP-1 levels, thereby promoting better weight management and healthy blood sugar
For diabetics or those at risk, these changes could translate into improved blood sugar management and reduced reliance on medications
The research team stated, "We have provided direct genetic evidence that variants in the drug's target gene create differences in treatment response." They added, "Using genetic information, we can predict which drug will work best for each patient and what side effects to expect before starting treatment." In a commentary published alongside the study in Nature, Ruth J.F
& Majumdar, S
To test whether the effects of GLP-1(2836) require its ability to interact with MTP, we knocked down MTP expression using a siRNA and repeated our Seahorse experiments
Structure Therapeutics CEO Ray Stevens thinks there will still be plenty of room in the market by then